Toronto Stock Exchange Symbol: MS
EDMONTON, Feb. 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at The 11th Annual BIO CEO & Investor Conference in New York.
WHEN: Monday February 9th at 2:45pm (Eastern Time) WHERE: Waldorf-Astoria, New York City About BIO CEO & Investor Conference ----------------------------------- This conference aims to bring together institutional investors, industry analysts, and senior biotechnology executives in a neutral and collaborative forum to examine investment opportunities and issues affecting the industry. For more information visithttp://ceo.bio.org/opencms/ceo/2009/index.jsp. About BioMS Medical Corp. -------------------------
BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com.
This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that ma
|SOURCE BioMS Medical Corp.|
Copyright©2009 PR Newswire.
All rights reserved